Everything below concerns angiotensin IV. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2025-08-30. Where a claim depends on a specific study, the study is described rather than over-claimed.
The compound originated from work on angiotensin IV, a peptide fragment of the renin-angiotensin system. Researchers modified angiotensin IV-related structures to produce molecules with altered stability and activity. Dihexa emerged from that effort and was reported to promote dendritic spine growth in cultured neurons. Some studies link its effects to hepatocyte growth factor signaling and the c-Met receptor, while other work points to insulin-regulated aminopeptidase. The precise primary target remains a subject of investigation, and findings may depend on cell type, assay conditions, and species.
In animal research, dihexa has been administered through several routes, and reports describe improved performance on spatial learning and memory tasks in rodents. These results are frequently cited in discussions of nootropic compounds. However, species differences, small sample sizes, and varied testing protocols limit how far the findings can be generalized. No large randomized controlled trials in humans have established efficacy or long-term safety. Claims about human cognitive enhancement therefore remain speculative, and the compound is best described as an experimental laboratory substance rather than a proven therapeutic or supplement.
Dihexa is a synthetic compound studied in laboratory and animal models for effects on synaptic connectivity and cognitive performance. It is often described as a peptide analog because its structure incorporates amino acid residues linked to a hexanoic acid group. The molecule is not a naturally occurring human hormone or neurotransmitter. Its name appears in research literature and online discussions, but it has not been approved as a medicine by major regulatory agencies. Most information comes from preclinical experiments rather than controlled human trials.
Dihexa is not approved as a medicine in major regulatory jurisdictions. It is commonly sold as a research chemical for laboratory use, though such products may not be standardized or independently verified. Scientific literature on dihexa includes in vitro assays, rodent studies, and reviews that discuss its proposed mechanism. The distinction between peer-reviewed findings and commercial promotion is important when evaluating available information. Open questions include its precise binding interactions, pharmacokinetics, and whether animal results translate to human biology.
Dihexa is a synthetic peptide derived from angiotensin IV, a naturally occurring fragment of the renin-angiotensin system. Researchers modified the angiotensin IV structure to improve metabolic stability and central nervous system activity. It is frequently described as a hepatocyte growth factor mimetic because it can activate the c-Met receptor pathway in experimental systems. Its development reflects interest in small peptides that influence synaptic plasticity and cognitive processes. Most information comes from preclinical studies rather than controlled human trials.
The compound has been examined in animal models for effects on learning, memory, and synaptic connectivity. Some reports describe increased dendritic spine density and improved performance on certain behavioral tasks after administration in rodents. These findings are often cited in discussions of nootropic research peptides, but replication across independent laboratories remains limited. The absence of published phase 1 or phase 2 clinical trial data makes it difficult to assess safety, effective routes, or long-term outcomes in humans. Consequently, claims about cognitive benefits in people remain speculative.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic peptide analog | Structural features include amino acid residues and a hexanoic acid group. |
| Common synonyms | PNB-0408; N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide | Names vary by source and should be verified. |
| Origin | Angiotensin IV research | Developed as a modified analog in academic laboratories. |
| Primary research focus | Synaptic growth and cognition | Studied mainly in cultured neurons and rodent models. |
| Regulatory status | Not approved as a drug | No accepted human therapeutic or supplement status. |
Regulatory treatment varies by country. Dihexa does not appear in major pharmacopeias as a licensed therapeutic substance. Suppliers may use labels such as research use only or not for human consumption. Such labels reflect legal and quality-control boundaries rather than evidence of clinical benefit. Importation, possession, and sale can be restricted depending on local laws, and enforcement focuses on claims, distribution channels, and product categories. These rules can change, and they differ from rules for approved medicines.
Dihexa is a synthetic peptide studied in preclinical neuroscience. It is often described as an angiotensin IV analog or derivative. The compound also appears under research codes such as PNB-0408 and N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide. It is not an approved drug, and it is not a conventional vitamin or nutrient. In many jurisdictions, material sold as dihexa is handled as a research chemical rather than a medicine or supplement. This classification affects how the material is labeled and distributed.
Development of dihexa has been linked to academic research on synaptogenesis, the formation of new synapses. Preclinical studies in rodents have examined its effects on learning and memory tasks. These studies are often cited in discussions about cognitive enhancement, but they do not establish safety or efficacy in humans. The compound's patent and commercial history is limited, and it is not widely available through pharmaceutical channels. Most information comes from animal models and in vitro experiments. Researchers continue to explore its basic biology rather than clinical applications.
Dihexa is not approved for human use in the United States or the European Union. It is commonly sold as a research chemical, a category that may not require the same regulatory review as medicines. Buyers should note that product labels may lack independent verification of identity or purity. The legal status can vary by country, and importation may be restricted. Reliable information about sourcing and quality is often scarce. Scientific publications typically use synthesized material from laboratories rather than commercial consumer products.
Dihexa is a synthetic peptide studied in laboratory research. It is often described as an angiotensin IV analog or a hepatocyte growth factor mimetic. The compound emerged from investigations into angiotensin IV and its effects on neural pathways. It is not an approved medication, and controlled human trials are lacking. In literature and online forums, it is discussed mainly as a research chemical. Its chemical name appears as N-hexanoic-Tyr-Ile-(6-aminohexanoic amide) in some sources.
Regulatory and commercial contexts differ from clinical medicine. Dihexa is not approved as a drug by major agencies, and no published human trials establish its safety or efficacy. It is often sold as a research chemical labeled for laboratory use only. Suppliers may provide certificates of analysis, but purity and identity depend on the specific batch. Legal status varies by country and may treat such compounds as unapproved substances for human consumption.
Dihexa is a synthetic peptidomimetic derived from angiotensin IV, a naturally occurring peptide fragment. It was created as a research compound to explore central nervous system signaling rather than as an approved therapeutic. Early work described it as a small, orally available molecule in rodent studies. Its structure combines tyrosine, isoleucine, and aminohexanoic acid components with a hexanoic acid cap. The compound is commonly referred to by the research code PNB-0408.
A great number of software tools for protein structure prediction exist. Approaches include homology modeling, protein threading, ab initio methods, secondary structure prediction, and transmembrane helix and signal peptide prediction. In particular, deep learning based on long short-term memory has been used for this purpose since 2007, when it was successfully applied to protein homology detection and to predict subcellular localization of proteins. Some recent successful methods based on the CASP experiments include I-TASSER, HHpred and AlphaFold. In 2021, AlphaFold was reported to perform best. Knowing the structure of a protein often allows functional prediction as well. For instance, collagen is folded into a long-extended fiber-like chain and it makes it a fibrous protein. Recently, several techniques have been developed to predict protein folding and thus protein structure, for example, Itasser, and AlphaFold.
Bryant Park is a 9.6-acre (3.9 ha), privately managed public park in the New York City borough of Manhattan. It is located between Fifth Avenue and Avenue of the Americas (Sixth Avenue) and between 40th and 42nd Streets in Midtown Manhattan. The eastern half of Bryant Park is occupied by the Main Branch of the New York Public Library. The western half contains a lawn, shaded walkways, and amenities such as a carousel, and is located entirely over an underground structure that houses the library's stacks. The park hosts several events, including a seasonal "Winter Village" with an ice rink and shops during the winter. The first park at the site was opened in 1847 and was called Reservoir Square due to its proximity to the Croton Distributing Reservoir. Reservoir Square contained the New York Crystal Palace, which hosted the Exhibition of the Industry of All Nations in 1853 and burned down in 1858. The square was renamed in 1884 for abolitionist and journalist William Cullen Bryant. The reservoir was demolished in 1900 and the New York Public Library's main branch was built on the site, opening in 1911. Bryant Park was rebuilt in 1933–1934 to a plan by Lusby Simpson. After a period of decline, it was restored in 1988–1992 by landscape architects Hanna/Olin Ltd. and architects Hardy Holzman Pfeiffer Associates, during which the park was rebuilt and the library's stacks were built underneath. Further improvements were made in the late 20th and early 21st centuries.
Single-domain antibodies have been tested as a new therapeutic tool against multiple targets. In mice infected with influenza A virus subtype H5N1, nanobodies directed against hemaglutinin suppressed replication of the H5N1 virus in vivo and reduced morbidity and mortality. nanobodies targeting the cell receptor binding domain of the virulence factors toxin A and toxin B of Clostridioides difficile were shown to neutralize cytopathic effects in fibroblasts in vitro. Nanobody conjugates recognizing antigen presenting cells have been successfully used for tumor detection or targeted antigen delivery to generate strong immune response. Orally available single-domain antibodies against E. coli-induced diarrhoea in piglets have been developed and successfully tested. Other diseases of the gastrointestinal tract, such as inflammatory bowel disease and colon cancer, are also possible targets for orally available single-domain antibodies. Detergent-stable species targeting a surface protein of Malassezia furfur have been engineered for use in anti-dandruff shampoos. As an approach for photothermal therapy nanobodies binding to the HER2 antigen, which is overexpressed in breast and ovarian cancer cells, were conjugated to branched gold nanoparticles (see figure). Tumor cells were destroyed photothermally using a laser in a test environment. Caplacizumab, a single-domain antibody targeting von Willebrand factor is in clinical trials for the prevention of thrombosis in patients with acute coronary syndrome.
Psilocybin and psilocin are listed as Schedule I drugs under the United Nations 1971 Convention on Psychotropic Substances. However, mushrooms containing psilocybin and psilocin are not unlawful in some parts of the world. For example, in Brazil they are legal, but extractions from the mushroom containing psilocybin and psilocin remain unlawful. In the United States, growing or possessing Psilocybe cubensis mushrooms is unlawful in all states, but it is legal to possess and buy the spores for microscopy purposes. However, Denver, Colorado, decriminalized them for those 21 and up on May 8, 2019. Oakland, California, followed suit, decriminalizing psilocybin-containing mushrooms as well as the peyote cactus on June 4, 2019. Santa Cruz, California, decriminalized naturally occurring psychedelics, including psilocybin mushrooms, on January 29, 2020. On November 3, 2020, the state of Oregon decriminalized possession of psilocybin mushrooms for recreational use and granted licensed practitioners permission to administer psilocybin mushrooms to individuals age 21 years and older. In 1978, the Florida Supreme Court ruled in Fiske vs Florida that possession of psilocybin mushrooms is not unlawful, in that the mushrooms cannot be considered a "container" for psilocybin based on how the law is written, i.e., it does not specifically state that psilocybin mushrooms themselves are unlawful, but that the hallucinogenic constituents in them are.
=== Robert Bilott investigation === In the Autumn of 2000, lawyer Robert Bilott, a partner at Taft Stettinius & Hollister, won a court order forcing DuPont to share all documentation related to PFOA. This included 110,000 files, consisting of confidential studies and reports conducted by DuPont scientists over decades. By 1993, DuPont understood that "PFOA caused cancerous testicular, pancreatic and liver tumors in lab animals" and the company began to investigate alternatives. However, because products manufactured with PFOA were such an integral part of DuPont's earnings, $1 billion in annual profit, they chose to continue using PFOA. Bilott learned that both "3M and DuPont had been conducting secret medical studies on PFOA for more than four decades", and by 1961 DuPont was aware of hepatomegaly in mice fed with PFOA. Bilott exposed how DuPont had been knowingly polluting water with PFOAs in Parkersburg, West Virginia, since the 1980s. In the 1980s and 1990s, researchers investigated the toxicity of PFOA. Regarding a secret agreement between 3M and the government of Jersey (UK) to not perform group testing of residents and to help 3M avoid a class action, Billott told The Guardian: "I've not seen something like this where there's an agreement to try to help the company against claims by others, Particularly if it's something affecting public health and safety or research." For his work in the exposure of the contamination, Bilott received several awards including The Right Livelihood Award in 2017.
Sources: en.wikipedia.org
In reaction that is the reverse of its biosynthesis, asparagine is hydrolyzed to aspartate by asparaginase. Aspartate then undergoes transamination to form glutamate and oxaloacetate from alpha-ketoglutarate. Oxaloacetate, which enters the citric acid cycle (Krebs cycle).
==== NMR techniques ==== The most common NMR techniques used when discriminating chiral compounds are 1H-NMR, 19F-NMR and 13C-NMR. 1H-NMR is the primary technique used to assign absolute configuration. 19F-NMR is almost exclusive applied to optical purity studies, and 13C-NMR is primarily used to characterize substrates that do not have protons that are directly bonded to an asymmetrical carbon atom.
=== 2016: Federal Supreme Court appeal === Following the CAS finding, the sole remaining avenue for appeal was the Federal Supreme Court of Switzerland, under whose jurisdiction the CAS sits. An appeal was lodged on 10 February, arguing that the CAS did not have legal grounds to conduct a de novo hearing and could have appealed the AFL Tribunal's verdict only based on legal error or gross unreasonableness. During the year, both parties submitted paperwork in German to the Federal Supreme Court. The court deliberated on the written submissions, and on 11 October 2016 dismissed the appeal, upholding the guilty verdicts and the suspensions:
In biology, hemostasis or haemostasis is a process to prevent and stop bleeding, meaning to keep blood within a damaged blood vessel (the opposite of hemostasis is hemorrhage). It is the first stage of wound healing. Hemostasis involves three major steps:
Austin was involved in the concluding segment at ECW One Night Stand on June 12 in which he had a beer bash with the ECW locker room. He also appeared on the internet themed event Cyber Sunday in 2007 and 2008. Austin also made appearenced to promote WWE material, like the WWE Films' production The Condemned, the revival of Tough Enough in 2011.
Sources: en.wikipedia.org
Dihexa is a synthetic peptide-like compound studied primarily in preclinical models. It is often classified as an angiotensin IV analog and has been investigated for effects on neuronal connectivity. It is not an approved drug or dietary supplement.
The exact mechanism is uncertain. Some research proposes activation of hepatocyte growth factor/c-Met signaling, while other evidence implicates insulin-regulated aminopeptidase. Multiple pathways may contribute, depending on the experimental system.
Published large-scale human trials are lacking. Most available data come from cell cultures and animal studies. As a result, human safety, appropriate dosing, and clinical effectiveness are not established.
Dihexa is a synthetic peptide derived from angiotensin IV and studied for effects on synaptic plasticity. It is often described as a hepatocyte growth factor mimetic. It is not an approved medication.